Supernus Pharmaceuticals, Inc. (United States) has no DMF, CEP or site registration linked in our records. 4 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Supernus Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/supernus-pharmaceuticals-inc

Overview

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company works on providing innovative therapeutic options for patients with neurological disorders through its pipeline of internally developed product candidates.

Therapeutic areas

FDA compliance signals

4 FDA enforcement records linked to this company.

  • recall — Class III2026-09-09

    Failed dissolution specifications.

  • recall — Class III2026-07-29

    Failed Dissolution Specifications

  • 4832017-02-03

    Late submission of quarterly safety reports

  • recall — Class II2016-10-26

    Superpotent Drug: Failure of assay specifications in the capsule.

For suppliers

Is this Supernus Pharmaceuticals, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.